Most cases of Merkel cell carcinoma occur in elderly people with the average age of presentation being 69 years. 1 Increased frequency has been reported in sun-exposed parts of the body and after immunosuppression. According to the US Surveillance Epidemiology and End Results Program (SEER database), the estimated incidence per 100 000 people is 0.23 in the white population and 0.01 in the black population. 1, 2 Although many small studies have been published on the treatment of Merkel cell carcinoma, so far no gold standard has been established. 3 Current treatment options are surgery alone, radiotherapy alone or surgery with postoperative radiotherapy. Owing to the rareness of the disease, very little data are available on the efficacy of chemotherapy and the results are conflicting. 4, 5 Overall 5-year survival ranges from 31 to 74%. 6 Targeted anticancer therapies have been found to be very promising options in the treatment of different forms of cancer such as renal cell carcinoma 7, 8 and gastrointestinal stromal tumors. 9, 10 So far no clinical trials using small molecules for Merkel cell carcinoma have been published. Moreover, data available on the expression of possible therapy targets in Merkel cell carcinoma are very limited. Only c-kit, a receptor tyrosine kinase, was found to be expressed in 15-90% of Merkel cell carcinoma samples. [11] [12] [13] [14] [15] [16] In the present study, we have assessed the expression of the possible molecular targets vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGFreceptor 2 (VEGF-R2), platelet-derived growth factor (PDGF)-a and PDGF-b, epidermal growth factor receptor (EGFR), Her-2/Neu (c-erbB-2), c-kit (CD117), Mcl-1 and Bmi-1 in 32 samples of Merkel cell carcinoma to determine if targeted therapy could be a possible treatment option. C-kit-positive samples were analyzed for the most common mutations in exons 9 and 11 using direct DNA sequencing. 
Materials and methods

Patients
Tissue Microarray
Before analysis, H&E-stained sections from each sample were evaluated and the suitability of inclusion for the study was determined. Sections (2-3 mm) were used for the analysis. The suitability of the tissue was evaluated using a number of inclusion criteria such as the size (1-2 mm in depth and at least 5 mm in length and width), as well as other features such as appropriate fixation, absence of significant electrosurgical device lesions, signs of acidic decalcifying agents and the presence of 
Immunohistochemistry
Dewaxed and rehydrated tissue microarrays were subjected to antigen retrieval in a microwave oven (600 W) employing the appropriate buffer ( Table 2) . Blocking of unspecific binding was achieved with 5% TBS/BSA (Sigma-Aldrich, Germany) for 1 h at room temperature. The primary antibody (Table 2) and appropriate negative and positive controls were applied at 41C overnight. A secondary biotinylated antibody (1:200, Multilink; Dako, Denmark) in 1% TBS/BSA was included for 1 h at room temperature, followed by alkaline phosphatase-conjugated streptavidin-AP/TBS/BSA (1:250; Dako) for 1 h at room temperature. Visualization was performed by fast red (Sigma-Aldrich, St Louis, MO, USA) and counterstained by hemalaun. Samples were analyzed using an Olympus BH-2 microscope.
Specimen Classification Based on Immunohistochemical Results and Morphological Features
We used an immunoreactivity score proposed by Sinicrope et al 19 to evaluate both the intensity of immunohistochemical staining and the proportion of the stained tumor cells. The staining intensity was subclassified as follows: 1, weak; 2, moderate; or 3, strong. The positive cells were quantified as a percentage of the total number of tumor cells and the proportions were assigned to one of five categories: 0, o5%; 1, 5-25%; 2, 26-50%; 3, 51-75%; and 4, 475%. The percentage of positivity of the tumor cells and the staining intensity were then multiplied to generate the immunoreactivity score for each of the tumor specimens. Mean immunoreactivity score was calculated from the three samples per patient. The expression pattern of each marker in the complete tumor samples was determined independently by two experienced investigators (MB and BME). An attempt to avoid observer bias was made by repeating the evaluation of protein expression at two different time points and without knowledge of patients' clinical data.
DNA Sequence Analysis
Isolation of DNA from paraffin-embedded tumor tissue Genomic DNA was prepared from 4-to 8.5-mm-thick sections of c-kit-positive paraffin-embedded tumor material using the QIAamp DNA Mini kit (Qiagen, Hilden, Germany). Paraffin blocks were trimmed to minimize the amount of non-neoplastic tissue before sectioning. A 100 ng portion of genomic DNA was amplified in 50 ml PCR mixtures using BD Advantage 2 (Clonetech; BD Biosciences, Erembodegem, Belgium) according to the manufacturers' instructions.
Design of primers
Primers specific for c-kit exons 9 and 11 were designed with the use of Primer Designer Software (Scientific and Education Software, Durham, NC, USA). The primers used are listed in Table 3 . VEGF-A, vascular endothelial growth factor A; VEGF-C, vascular endothelial growth factor C; VEGF-R2, VEGF-receptor 2; PDGF-a, plateletderived growth factor alpha; PDGF-b, platelet-derived growth factor beta; EGFR, epidermal growth factor receptor; c-erbB-2, HER-2/Neu; CD117, c-kit; Mcl-1, myeloid cell leukemia-1; Bmi-1, B-cell-specific moloney murine leukemia virus site 1; RTU, ready to use; EDTA, ethylenediaminetetraacetic acid. 
Results
Clinical Data
Of the 29 patients, 17 (59%) were male and 12 (41%) were female, ranging in age from 50 to 96 years (mean 76.8 years). Nineteen tumors (66%) were located in the head and neck region and 10 (34%) on the extremities. Twenty-three patients (79%) presented with early disease (stage I), four with stage II (14%) and two with stage III (7%). Eleven (40%) are alive without disease and two (7%) are alive with disease. Eleven died of the disease (40%) and five died of other causes (13%). Table 1 shows the complete clinical data.
Microscopy
As described previously by Sur et al, 20 we observed two distinct types of Merkel cell carcinoma cells. Nine samples showed morphology similar to classical small cell carcinoma. In 18 samples, the carcinoma cells were significantly bigger (larger than 3 lymphocytes) and showed high mitotic activity and multiple nucleoli. In five samples, both morphologies were present.
Immunohistochemistry
Interestingly, with the exception of c-kit, the investigated proteins were usually uniformly expressed in all tumor cells (Figure 1 ).
c-kit
Two out of 32 (7%) Merkel cell carcinoma samples were positive for c-kit. Both samples belonged to the same patient and showed a membranous staining pattern in a small number of tumor cells. Immunoreactivity score was 2.7 in one and 3.7 (mean 3.2) in the other sample. Both samples belonged to the large cell carcinoma group.
Mcl-1
Out of 32 samples, 25 (88%) were positive for Mcl-1 in the cell cytoplasm. Mean immunoreactivity score of the positive samples was 6.4. There was no significant difference between small and large cells.
Bmi-1
Out of 32 samples, 24 (75%) were positive for Bmi-1 in the cell nuclei and cytoplasm. Mean immunoreactivity score of the positive samples was 8. There was no significant difference between small and large cells.
VEGF-A
Out of 32 samples, 29 (91%) were positive for VEGF-A in the cell cytoplasm. Although almost all samples expressed VEGF-A, the staining intensity was generally low with a mean immunoreactivity score of 4.7. There was no significant difference between small and large cells.
VEGF-C
Out of 32 samples, 24 (75%) were positive for VEGF-C in the cell cytoplasm. As with VEGF-A, the mean staining intensity was relatively low with an immunoreactivity score of 4.4. There was no significant difference between small and large cells.
VEGF-R2
Out of 32 samples, 28 (88%) were positive for VEGF-R2 with a membranous and cytoplasmic staining pattern. Almost all samples expressed VEGF-R2, some samples with a very high intensity. The mean immunoreactivity score of the positive samples was 8.6. VEGF-R2 expression was higher in the large cell group, although the difference failed to reach statistical significance (P ¼ 0.007).
PDGF-b
Only 4 samples out of 32 (13%) expressed PDGF-b in the cell cytoplasm. All of those samples belonged to the large cell group. Two samples were with an intensity score of 4 and two with a score of 8 (mean 6).
PDGF-a
Out of 32 samples, 23 (72%) were positive for PDGF-a with a partially cytoplasmic and partially membranous staining pattern. The mean immunoreactivity score of the positive samples was 4.7. There was no significant difference between small and large cells.
Immunohistochemistry showed no positive staining for EGFR and Her-2/Neu. Staining pattern of all antibodies is shown in Figure 2 .
DNA Sequence Analysis
Paraffin-embedded samples of the two c-kit-positive tumors were screened for mutations in hot-spot Therapy targets in Merkel cell carcinoma M Brunner et al regions of c-kit (exons 9 and 11). However, no mutations leading to amino-acid changes in the mature protein could be detected.
Correlation of Target Expression and Clinical Outcome
Statistical analysis revealed no correlation between target expression and tumor remission, gender and tumor stage.
Discussion
Merkel cell carcinoma, a neuroendocrine neoplasm, is a highly proliferative epidermal tumor with a high rate of recurrence and metastasis and poor survival. Current treatment options did not significantly improve patients overall survival. Thus, advances in therapy will depend on novel therapeutic approaches. During the last decade, ) is directed against the erbB-2 receptor, which is also known as Her-2/Neu oncogene. Cetuximab (Erbitux s ) is active against the EGFR. In our samples, Merkel cell carcinoma cells did neither express EGFR nor Her-2/ Neu. Thereby, we could confirm the findings of Maubec et al, 21 who also could not detect any expression of these two receptors in Merkel cell carcinoma by immunohistochemistry.
The next group of targets in the protein kinase signalling network is receptor tyrosine kinases. Receptor tyrosine kinases are single-pass membrane proteins with an extracellular ligand binding and an intracellular kinase domain. Receptor tyrosine kinases function in cell signalling and transmit signals regulating growth, differentiation, adhesion, migration and apoptosis. [22] [23] [24] [25] [26] The receptor tyrosine kinase family consists of several subfamilies, including the epidermal growth factor receptors (EGFRs or ErbBs), the platelet-derived growth factor receptors (PDGFRs) and the VEGF receptors. 23 All of the above-mentioned subfamilies are known to be expressed in many cancers and play an important role in angiogenesis and tumor progression. 27, 28 In this study, we observed that VEGF-A, VEGF-C, VEGF-R2, PDGF-a and PDGF-b are expressed in Merkel cell carcinomas. Interestingly, all of the examined proteins were uniformly expressed throughout the tumors and their expression levels were rather low. There was a tendency toward higher expression in large cell tumors, although the difference did not reach statistical significance. This discrepancy was most pronounced in VEGF-R2. Furthermore, in most of the investigated samples VEGF-R2 was detectable in the cell cytoplasm and its expression level was significantly higher than that of the above-mentioned proteins. The reason for the differential expression of receptor tyrosine kinases in Merkel cell carcinoma is still unknown.
C-kit, a proto-oncogene involved in the activation of cell proliferation, is expressed not only in normal cells 29 but also in tumors of the solid aerodigestive tract. [30] [31] [32] The expression of c-kit (CD117) in Merkel cell carcinoma has been examined previously in five studies with a range of 15-95%. [11] [12] [13] [14] [15] [16] In our study, 7% of Merkel cell carcinoma samples expressed c-kit. We hypothesize that the discrepancy between the five studies can be explained by the small sample numbers and by different staining and evaluation methods utilized.
C-kit and VEGF-R2, together with VEGF-R1, VEGF-R3 and PDGFRs, are targets of two multitargeted inhibitors Sorafenib (Nexavar s ) and Sunitinib (Sutent s ). Sunitinib has been successfully tested in the treatment of renal cell carcinoma 7, 8 and gastrointestinal stromal tumors. 9, 10 Sorafenib is an effective anticancer agent directed against renal cell carcinoma 33, 34 and has been evaluated in phase I trials in solid tumors, melanoma and non-small-cell lung cancer. [35] [36] [37] In gastrointestinal stromal tumors, different c-kit mutations are known to predict survival and even more importantly response to treatment with tyrosine kinase inhibitors. 38, 39 The exons of c-kit that are most commonly affected by mutation are exons 9 and 11. Gastrointestinal stromal tumors with exon 11 mutations respond more frequently to targeted treatment than exon 9 mutations, while wild-type c-kit has the worst response rate. 38, 39 In two c-kit-positive samples of our study, no mutations leading to aminoacid changes in the mature protein could be detected. Based on our analysis of c-kit expression and mutation, c-kit does not seem to be a very promising candidate for targeted anticancer therapy in Merkel cell carcinoma.
Another way to affect tumor growth is to inhibit the expression of genes involved in cell proliferation and cell death by introduction of microRNAs or antisense oligonucleotides. 40 Recently, several antisense oligonucleotides targeting genes involved in neoplastic progression have been evaluated as potential therapeutic agents, one of them being Mcl-1. [41] [42] [43] Mcl-1, a member of the Bcl-2 protein family, is an antiapoptotic protein [44] [45] [46] and functions by avoiding cell damage-induced mitochondrial cytochrome c release. 47, 48 Although the definite mechanisms of how Mcl-1 promotes cell survival is not yet fully elucidated, the biological significance of Mcl-1 protein expression in supporting cell survival has been well documented in a number of solid and non-solid tumors. 41, [49] [50] [51] [52] [53] [54] [55] Therefore, the next logical step was specific inhibition of Mcl-1 expression by antisense oligonucleotides or microRNAs. 55 So far no study has investigated the expression of Mcl-1 in Merkel cell carcinoma. In our cohort, the majority of tumor samples showed a very high expression of Mcl-1. That makes Mcl-1 a very auspicious candidate for targeted therapy and validates further in vivo studies on the effect of Mcl-1 antisense oligonucleotides in Merkel cell carcinoma.
Bmi-1 is a transcriptional repressor that belongs to the polycomb-group family of proteins involved in hematopoiesis, regulation of proliferation and axial patterning. 56, 57 It has been found to be an important factor of self-renewal and senescence of various stem cells, [58] [59] [60] and its overexpression was shown to immortalize human mammary epithelial cells. 61 Bmi-1 is highly expressed in various human malignant tumors. [62] [63] [64] [65] [66] [67] [68] [69] The recently developed antisense Bmi-1 expression plasmid was able to inhibit proliferation of human leukemia cells in vitro. 70 Interestingly, we were able to demonstrate intense Bmi-1 expression in almost all Merkel cell carcinoma specimens of our cohort. That makes Bmi-1 another promising candidate for future antisense oligonucleotide therapies in patients with Merkel cell carcinoma.
Owing to the small number of tumor specimens, we could not detect any statistically relevant correlations between patients' clinical data and target expression. Also, we could not demonstrate an impact of the morphology on the course and aggressiveness of the disease. However, further studies will be needed to fully determine the impact of targeted therapy in Merkel cell carcinoma in vitro and in vivo, as the presence of a target does not always predict response to a targeted agent. 71 In summary, in this study we show for the first time that the therapy targets c-kit, Bmi-1, Mcl-1, VEGF-A and VEGF-C, VEGF-R2, PDGF-a and PDGFb are expressed in Merkel cell carcinoma. Considering the good results of targeted anticancer and antiangiogenic therapies in resent clinical trials, these results are very promising and validate further clinical studies on the use of multitargeted tyrosine kinase inhibitors and antisense oligonucleotides in Merkel cell carcinoma.
